Updates from December 2020
Jan 07, 2021•20 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The 1st episode of 2021 covers 5 FDA updates from December 2020
-Pralsetinib for RET-mutated medullary thyroid cancer
-The new HER2-targeting margetuximab
-Selinexor and the Boston study
-Relugolix, an oral GnRH antagonist
-Adjuvant osimertinib approved (ADAURA)
For the best experience, listen in Metacast app for iOS or Android